Journal
BLOOD
Volume 130, Issue 10, Pages 1243-1246Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-04-777987
Keywords
-
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [R01 DK 065029]
- UCLA Center for Accelerated Innovation, under National Heart, Lung, and Blood Institute, National Institutes of Health (UC CAI) [U54HL119893]
- National Center for Advancing Translational Sciences, National Institutes of Health (UCLA CTSI) [UL1TR001881]
Ask authors/readers for more resources
Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO). We previously demonstrated that ERFE messenger RNA expression and serum protein concentration increase in mice subjected to hemorrhage or EPO therapy, that ERFE acts on hepatocytes to suppress hepcidin, and that the resulting decrease in hepcidin augments iron delivery for intensified erythropoiesis. We also showed that ERFE contributes to pathological hepcidin suppression and iron overload in mice with non transfused beta-thalassemia. We now report the development and technical validation of a rabbit monoclonal antibody-based sandwich immunoassay for human ERFE. We use this assay to show that blood loss or EPO administration increases serum ERFE concentrations in humans, and that patients with both nontransfused and transfused b-thalassemia have very high serum ERFE levels, which decrease after blood transfusion. The assay should be useful for human studies of normal and disordered erythropoiesis and its effect on iron homeostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available